Skip to main content

Table 2 Forced vital capacity outcomes reported in the included trials

From: Comparing new treatments for idiopathic pulmonary fibrosis – a network meta-analysis

  Change in percent predicted FVC (%) or absolute change from baseline (L) No. with reduction in FVC >10%a b
Source FVC outcome Treatment Placebo P value Treatment Placebo P value
   No. of participants Mean (SD) No. of participants Mean (SD)   No. (%) No. (%)  
Pirfenidone          
Noble et al. 2011 [4] (Capacity 006) % pred 171 −9.0 (19.6) 173 −9.6 (19.1) 0.501 39 (23) 46 (27) 0.440
Noble et al. 2011 [4] (Capacity 004) % pred 174 −8.0 (16.5) 174 −12.4 (18.5) 0.001 35 (20) 60 (35) 0.01
Taniguchi et al. 2010 [5] Litres 104 −0.09 (0.20) 103 −0.16 (0.20) 0.042    
Azuma et al. 2005 [6] Litres 72 −0.03 (0.22) 35 −0.13 (0.19) 0.037 9 (13) 12 (36) 0.003
King et al. 2014 [7] (Ascend) Litres 278 −0.122 (0.4) 277 −0.262 (0.4) 0.001 46 (16.5) 88 (31.8) <0.00001
Nintedanib          
Richeldi et al. 2011 [25] % pred 85 −1.04 (9.1) 85 −6.0 (9.4) <0.001 20 (23.8) 37 (44.0) 0.004
  Litres 85 −0.06 (0.37) 85 −0.23 (0.37) 0.001    
Richeldi et al. 2014 [8] (INPULSIS-1) % pred 307 −2.8 (6.2) 204 −6.0 (6.2) <0.001 91 (29.5)c 88 (43.1) <0.001
  Litres 307 −0.095 (0.22) 204 −0.205 (0.22) <0.001    
Richeldi et al. 2014 [8] (INPULSIS-2) % pred 327 −3.1 (6.99) 217 −6.2 (6.99) <0.001 100 (30.4)e 79 (36.1)e 0.18
  Litres 327 −0.095 (0.23) 217 −0.205 (0.23) <0.001    
Inhaled NAC          
Homma et al. 2012 [24], Litres 38 −0.09 (0.3) 38 −0.15 (0.2) 0.27    
NAC triple therapy          
Raghu et al. 2012 [22], (PANTHER) Litres 77 −0.24 (0.4) 78 −0.23 (0.4) 0.85    
NAC          
IPFCRN, 2014 [23] (PANTHER) % Pred d 133 −4.37 (7.5) 131 −4.76 (7.3) 0.67    
  Litres d 133 −0.18 (0.3) 131 −0.19 (0.3) 0.77    
  1. In some trials the vital capacity was reported which has been assumed to translate to the FVC.
  2. Where not reported in individual trials measures of variance have been estimated from p-values reported using standard methodology.
  3. aNumber of participants with a reduction in mean FVC of >10% (or 200 ml where applicable). bNumber of participants with a reduction in mean FVC of >10% or death in ASCEND trial [7]. cBased on 309 patients in Nintedanib group. dFrom longitudinal analysis which adjusts for treatment time, interaction between time and treatment, age, sex, race and height; assumes that data were missing at random and no data were imputed. eBased on 329 patients in Nintedanib group and 219 patients in placebo group.